JP2014526561A - 皮膚剥脱のための組成物およびその使用 - Google Patents
皮膚剥脱のための組成物およびその使用 Download PDFInfo
- Publication number
- JP2014526561A JP2014526561A JP2014532028A JP2014532028A JP2014526561A JP 2014526561 A JP2014526561 A JP 2014526561A JP 2014532028 A JP2014532028 A JP 2014532028A JP 2014532028 A JP2014532028 A JP 2014532028A JP 2014526561 A JP2014526561 A JP 2014526561A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- solution
- retinol
- applying
- acidic solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 206010040844 Skin exfoliation Diseases 0.000 title claims description 126
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 474
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 238
- 239000011607 retinol Substances 0.000 claims abstract description 236
- 229960003471 retinol Drugs 0.000 claims abstract description 236
- 235000020944 retinol Nutrition 0.000 claims abstract description 236
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims abstract description 53
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 53
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 27
- 239000004310 lactic acid Substances 0.000 claims abstract description 26
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 26
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000243 solution Substances 0.000 claims description 298
- 238000000034 method Methods 0.000 claims description 203
- 239000003929 acidic solution Substances 0.000 claims description 136
- 238000011282 treatment Methods 0.000 claims description 81
- 238000004299 exfoliation Methods 0.000 claims description 78
- 238000005406 washing Methods 0.000 claims description 47
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 42
- 239000004094 surface-active agent Substances 0.000 claims description 33
- 239000003381 stabilizer Substances 0.000 claims description 31
- 230000037303 wrinkles Effects 0.000 claims description 29
- 230000006872 improvement Effects 0.000 claims description 24
- 230000008832 photodamage Effects 0.000 claims description 24
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 16
- 229940101267 panthenol Drugs 0.000 claims description 15
- 235000020957 pantothenol Nutrition 0.000 claims description 15
- 239000011619 pantothenol Substances 0.000 claims description 15
- 229940113096 isoceteth 20 Drugs 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 34
- 239000000126 substance Substances 0.000 abstract description 19
- 150000007513 acids Chemical class 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 11
- 239000006071 cream Substances 0.000 abstract description 6
- 230000000699 topical effect Effects 0.000 abstract description 6
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 abstract description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract description 2
- 230000035515 penetration Effects 0.000 abstract description 2
- 235000019155 vitamin A Nutrition 0.000 abstract description 2
- 239000011719 vitamin A Substances 0.000 abstract description 2
- 229940045997 vitamin a Drugs 0.000 abstract description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
- 229930003268 Vitamin C Natural products 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 381
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 40
- 229930002330 retinoic acid Natural products 0.000 description 40
- 229960001727 tretinoin Drugs 0.000 description 40
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 26
- 235000020945 retinal Nutrition 0.000 description 26
- 239000011604 retinal Substances 0.000 description 26
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 26
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 26
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 26
- 229960001755 resorcinol Drugs 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 206010015150 Erythema Diseases 0.000 description 19
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 16
- 229960000448 lactic acid Drugs 0.000 description 16
- 150000004492 retinoid derivatives Chemical class 0.000 description 15
- 230000000475 sunscreen effect Effects 0.000 description 15
- 239000000516 sunscreening agent Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 208000012641 Pigmentation disease Diseases 0.000 description 13
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 13
- 210000004207 dermis Anatomy 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 230000002207 retinal effect Effects 0.000 description 13
- 229960000342 retinol acetate Drugs 0.000 description 13
- 235000019173 retinyl acetate Nutrition 0.000 description 13
- 239000011770 retinyl acetate Substances 0.000 description 13
- 229940108325 retinyl palmitate Drugs 0.000 description 13
- 235000019172 retinyl palmitate Nutrition 0.000 description 13
- 239000011769 retinyl palmitate Substances 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 230000019612 pigmentation Effects 0.000 description 11
- 239000004909 Moisturizer Substances 0.000 description 10
- 230000002378 acidificating effect Effects 0.000 description 10
- 230000001815 facial effect Effects 0.000 description 10
- 230000001333 moisturizer Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 239000011928 denatured alcohol Substances 0.000 description 8
- 231100000321 erythema Toxicity 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 230000032798 delamination Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 210000000887 face Anatomy 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 229940061720 alpha hydroxy acid Drugs 0.000 description 6
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 6
- 210000000624 ear auricle Anatomy 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000007803 itching Effects 0.000 description 6
- 239000001630 malic acid Substances 0.000 description 6
- 235000011090 malic acid Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000011975 tartaric acid Substances 0.000 description 6
- 235000002906 tartaric acid Nutrition 0.000 description 6
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 230000007123 defense Effects 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 229960002510 mandelic acid Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229940002683 retin-a Drugs 0.000 description 5
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 4
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 4
- 206010047642 Vitiligo Diseases 0.000 description 4
- 238000010306 acid treatment Methods 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 229940089093 botox Drugs 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000002845 discoloration Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 210000001061 forehead Anatomy 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000037307 sensitive skin Effects 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 206010006784 Burning sensation Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 208000000069 hyperpigmentation Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000036555 skin type Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000008833 sun damage Effects 0.000 description 3
- 230000036561 sun exposure Effects 0.000 description 3
- 230000037072 sun protection Effects 0.000 description 3
- -1 2,6,6-trimethylcyclohex-1-enyl Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 206010033372 Pain and discomfort Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000882890 Renova Species 0.000 description 2
- 206010039580 Scar Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 238000011256 aggressive treatment Methods 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940002658 differin Drugs 0.000 description 2
- 238000005868 electrolysis reaction Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000004373 mandible Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229940059527 renova Drugs 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940036234 tazorac Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010024648 Livedo reticularis Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本願は、参照によりその全体が組み込まれる、2011年9月23日に出願された「COMPOSITIONS FOR SKIN EXFOLIATION AND USE THEREOF」と題される米国実用特許出願第13/243,567号の利益を主張する。
本明細書に記載される全ての刊行物、特許および特許出願は、各個別の刊行物、特許、または特許出願が、明確かつ個別に参照により組み込まれることが示されているのと同程度に、参照により本明細書に組み込まれる。
予備治療レジメンは、本明細書に記載される組成物および方法に関連して、皮膚の特徴を改善し得る。
予備洗浄溶液は、皮膚から垢および油を除去するのに十分な量等の、使用者の皮膚に利益を提供する量で皮膚に適用するために調製されるものである。洗浄溶液は、これに限定されないが、アルコール溶液を含み、典型的には、石鹸を含まず、水、洗剤、界面活性剤、湿潤剤、皮膚コンディショニング剤、pH調整剤、抽出物、防腐剤、芳香剤、および着色剤を含むが、皮膚から垢および油を除去するのに適したいずれの洗浄剤を使用することができる。一実施形態では、洗剤溶液は、アルコール溶液を含む。例示的な非限定的なアルコール溶液は、イソプロピルアルコール、水/常水、およびアセトンを含む。
様々な皮膚再生を刺激する酸が一緒に組み合わせられてよく、試験は、皮膚への適用に適した化粧品に組み込むために、それらの有効性および副作用を評価するために使用され得る。
レチノイン酸は、剥脱を加速し、皮膚に酸性溶液を適用した後の全体的なコラーゲンおよび細胞外マトリックスの発達を強化するのを補助する。以前に化学剥離治療に使用されてきたレチノイン酸溶液は、0.3%のレチノイン酸の濃度を有する処方を必要とする点で問題がある。さらに重要なことは、処方は、0.3%の一貫した量のレチノイン酸を有さないことが判明しており、治療後に過敏をもたらした。
皮膚の改善は、色素沈着および乾燥をもたらし得る太陽光線によって遅れるか、または悪化する可能性がある。したがって、保護組成物は、日光による損傷または乾燥を軽減するために、本開示の治療レジメンにおいて補正組成物と任意に組み合わせることができる補足組成物のクラスの1つである。
皮膚洗浄剤、酸性溶液、レチノール溶液、および溶液を適用するための説明書を含む、皮膚を剥脱するためのキットが本明細書において提供され、キットの成分のそれぞれは上に記載されている。
本開示は、皮膚の老化を剥脱し、皮膚の外見を改善するための方法にも関する。そのような方法は、本明細書に記載される有効量の組成物を送達するためのパッドまたは他の手段を皮膚に局所的に適用することを含む。
治療前の指示
非常に表面的な剥離を行う前の1週間、患者は、次の製品および/または手順を避けるべきである:電気分解、無駄毛処理、除毛クリーム、レーザー脱毛。また、BOTOX(登録商標)注入を受けた患者は、皮膚剥脱治療を受ける前にそれらの治療の完全な効果が見られるまで待つべきである。
医療専門家が手順を行う場合、手順前に説明と同意を得るべきである。医療専門家は、患者が現在使用している全ての局所用製品および薬剤を見直し、患者が全ての治療前の指示に従ったかを確認し、手順を行う前に皮膚を慎重に検査するべきである。以前の過敏ないずれかの領域が観察された場合、それらの領域に対して手順を行うべきではない。
上述のように、洗浄(予備溶液)は、イソプロピルアルコール、水/常水、およびアセトンで調製される。
非常に表面的なレチノール溶液(% W/W)は、3%のレチノール結晶(Palm Pharmaceuticals,Inc.)を97%のSDアルコールSDA 40−2(200 proof;Remet Corp.)と混合することにより調製される。
ステップ3の適用後、30+の日焼け止め(例えばEnvironmental Defense Sunscreen(商標)SPF 30+)を多めに顔全体に適用する。首およびデコルテが治療された場合、適用はこれらの領域にも拡大される。
レチノール溶液は治療の一部として使用されるため、手順直後、皮膚は淡黄色の色合いを帯びるが、これは一時的であり、典型的には1〜2時間で消える。患者は、顔を洗う前に、黄色の色合いが完全に消える(1〜2時間)まで待つか、または夜まで待つべきである。
治療前の指示および剥脱/剥離手順は、実施例1に上述される通りである。表面的な皮膚剥脱プロトコルは、大半の場合、患者により深い剥脱を提供する。
上述のように、洗浄(予備溶液)は、イソプロピルアルコール、水/常水、およびアセトンで調製される。
表面的なレチノール溶液(% W/W)は、5%のレチノール結晶(Palm Pharmaceuticals,Inc.)を95%のSDアルコールSDA 40−2(200 proof;Remet Corp.)と混合することにより調製される。
ステップ3の適用後、30+SPFの日焼け止め(例えばEnvironmental Defense Sunscreen(商標)SPF 30+)を多めに顔全体に適用する。首およびデコルテが治療された場合、適用はこれらの領域にも拡大される。
レチノール溶液は治療の一部として使用されるため、手順直後、皮膚は淡黄色の色合いを帯びるが、これは一時的であり、典型的には1〜2時間で消える。患者は、顔を洗う前に、黄色の色合いが完全に消える(1〜2時間)まで待つか、または夜まで待つべきである。
レチノイン酸の代替え化合物としてのレチノールの使用を試験するために、3つの研究が行われた。2%(w/w)の濃度のレチノールが最初に試験され、必要に応じて増加された。最初の2つの研究は、実施例1および2に上述される1回の剥脱(剥離)で使用されたときの剥離および耐性をレチノイン酸0.3%と比較することにより、製剤および用量を確立した。3つめの研究は、一連の3回の剥離手順で使用されたときの選択された製剤および投薬量の有効性および耐性をレチノイン酸0.3%と比較した。
本研究の目的は、剥離の有効性および耐性に関して、レチノール2%がレチノイン酸0.3%と同等であるかを判断することであった。
1.全顔に非常に表面的な剥離(準備および剥離)1回。
2.左側:2ccのレチノール2%
3.右側:2ccのレチノイン酸0.3%
左側:左側は、右側よりも多い剥離を示す。
右側:右側は、左側よりも多い剥離を示す。
差なし:両側の剥離量において識別可能な差はなく、両側とも等しく剥離した。
0=剥離なし:皮膚は全く滑らかであり、剥離は見られない。
1=最小限の剥離:皮膚は滑らかであり、剥離/剥離片の領域は少ない。
2=軽度の剥離:皮膚は一般的に滑らかであり、剥離/剥離片の領域がいくつかある。
3=中程度の剥離:顔の複数の領域に顕著な剥離/剥離片がある。
4=重度の剥離:顔の複数の領域に皮膚剥離の大きな剥離片/薄片がある。
次の研究は、レチノールの割合を3.0%に増加したときの効果を判断するために行われ、結果をレチノイン酸0.3%と比較した。
本研究の目的は、剥離の有効性および耐性に関して、レチノールの処方および割合がレチノイン酸0.3%と同等であるかを判断することであった。
1.全顔に非常に表面的な剥離(準備および剥離)1回。
2.左側:2ccのレチノール3%
・オイル処方(N=20)
・オイルなし処方(N=6)
3.右側: 2ccのレチノイン酸0.3%
研究ステップは、アルコール中レチノール3%(すなわちオイルなし)が、一連の剥離に使用されるとき、レチノイン酸0.3%と同等の有効性(光による損傷における改善等)、剥離有効性、および耐性を有するかを判断するために行われた。
全顔に非常に表面的な剥離(準備および剥離)1回
左側:2ccのレチノール3%(オイルなし)
右側:2ccのレチノイン酸0.3%
左側:左側は、右側よりも多い剥離を示す。左側は、光による損傷においてもさらなる改善を示す。
右側:右側は、左側よりも多い剥離を示す。右側は、光による損傷においてもさらなる改善を示す。
差なし:両側の剥離量において識別可能な差はなく、両側とも等しく剥離した。光による損傷の見かけにおいて、両側とも等しく改善された。
Claims (20)
- 皮膚剥脱治療に使用するための組成物であって、薬学的に許容される担体と、少なくとも3%、少なくとも4%、少なくとも5%、少なくとも6%、少なくとも7%、少なくとも8%、少なくとも9%、少なくとも10%以上のレチノール溶液とを含み、前記レチノール溶液が、実質的に純粋なレチノール源から調製される、組成物。
- 前記組成物が、界面活性剤、安定剤、又はそれらの両方を実質的に含まない、請求項1に記載の組成物。
- 前記レチノール溶液が、少なくとも約98%の純度を有する、請求項1に記載の組成物。
- 前記レチノール溶液が、少なくとも98%の純度の粉末から調製される、請求項1に記載の組成物。
- 前記レチノール溶液が、3%または5%の濃度で存在する、請求項1に記載の組成物。
- 皮膚を剥脱するためのキットであって、
a.皮膚洗浄剤と、
b.酸性溶液と、
c.実質的に純粋なレチノール源から調製されるレチノール溶液と、
d.溶液を適用するための説明書と、を含む、キット。 - 前記皮膚洗浄剤が、イソプロピルアルコール溶液を含む、請求項6に記載のキット。
- 前記酸性溶液が、乳酸、サリチル酸、およびレゾルシノールを含む、請求項6に記載のキット。
- 前記酸性溶液が、イソセテス−20、パンテノール、またはそれらの組み合わせをさらに含む、請求項8に記載のキット。
- 前記レチノール溶液が、少なくとも約3%、少なくとも4%、少なくとも5%、少なくとも6%、少なくとも7%、少なくとも8%、少なくとも9%、少なくとも10%以上の濃度を含む、請求項6に記載のキット。
- 前記レチノール溶液が、界面活性剤、安定剤、またはそれらの両方を含有しない、請求項6に記載のキット。
- 前記レチノール溶液が、少なくとも約98%の純度を有する、請求項6に記載のキット。
- 皮膚を剥脱するための方法であって、
a.剥脱される皮膚を洗浄することと
b.前記皮膚に酸性溶液を適用することと、
c.レチノール溶液であって、少なくとも約3%、少なくとも4%、少なくとも5%、少なくとも6%、少なくとも7%、少なくとも8%、少なくとも9%、少なくとも10%、またはそれ以上の濃度のレチノールを含有し、実質的に純粋な源から調製され、かつ前記酸性溶液が前記皮膚に適用された後に前記皮膚に適用される、レチノール溶液を、前記皮膚に適用することと、を含む、方法。 - (a)が、前記皮膚にアルコール溶液を適用することを含む、請求項13に記載の方法。
- 前記アルコール溶液が、イソプロピルアルコール溶液を含む、請求項14に記載の方法。
- 前記レチノール溶液が、前記酸性溶液が前記皮膚に適用された後に、前記皮膚に適用され、前記酸性溶液が、界面活性剤または安定剤を含有しない、請求項13に記載の方法。
- 前記酸性溶液が、乳酸、サリチル酸、およびレゾルシノールの組み合わせを含む、請求項13に記載の方法。
- 前記酸性溶液が、イソセテス−20、パンテノール、またはこれらの組み合わせをさらに含む、請求項17に記載の方法。
- 前記方法が、全体的な光による損傷、小皺および皺の現れ、皮膚の色合いのむら、またはそれらの組み合わせを改善する、請求項13に記載の方法。
- 前記改善が、未治療の皮膚と比較して、少なくとも1.5倍、または少なくとも2倍である、請求項19に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/243,567 | 2011-09-23 | ||
US13/243,567 US10639252B2 (en) | 2011-09-23 | 2011-09-23 | Compositions for skin exfoliation and use thereof |
PCT/US2012/056681 WO2013044111A1 (en) | 2011-09-23 | 2012-09-21 | Compositions for skin exfoliation and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014526561A true JP2014526561A (ja) | 2014-10-06 |
JP6257518B2 JP6257518B2 (ja) | 2018-01-10 |
Family
ID=47909867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014532028A Expired - Fee Related JP6257518B2 (ja) | 2011-09-23 | 2012-09-21 | 皮膚剥脱のための組成物およびその使用 |
Country Status (11)
Country | Link |
---|---|
US (2) | US10639252B2 (ja) |
EP (1) | EP2758044A4 (ja) |
JP (1) | JP6257518B2 (ja) |
KR (1) | KR102158395B1 (ja) |
CN (2) | CN111920764A (ja) |
AU (5) | AU2012312090A1 (ja) |
CA (1) | CA2849893C (ja) |
HK (1) | HK1200345A1 (ja) |
MX (2) | MX370444B (ja) |
SG (2) | SG10201601101UA (ja) |
WO (1) | WO2013044111A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016084337A (ja) * | 2014-05-13 | 2016-05-19 | ロート製薬株式会社 | 外用組成物 |
CN104293813B (zh) * | 2014-09-28 | 2017-08-25 | 深圳华大基因股份有限公司 | 皮肤剥脱综合征新的致病基因及其编码蛋白质和应用 |
CN107530119B (zh) * | 2015-02-19 | 2021-05-07 | 凯蒂森特生物医药公司 | 用于产生热量的医疗装置和使用它的治疗方法 |
US9248160B1 (en) | 2015-07-28 | 2016-02-02 | Zo Skin Health, Inc. | Post-procedure skin care systems, compositions, and methods of use thereof |
US11324679B2 (en) | 2016-05-12 | 2022-05-10 | Conopco, Inc. | Method for stabilizing retinoic acid precursors and a skin benefit composition with stabilized retinoic acid precursors |
EA201991003A1 (ru) | 2016-12-21 | 2019-12-30 | Юнилевер Н.В. | Композиции для личной гигиены, содержащие малорастворимые соединения |
WO2018113634A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
CN114767562B (zh) | 2016-12-21 | 2024-05-10 | 联合利华知识产权控股有限公司 | 具有氨基酸和烟酰胺化合物的局部皮肤增亮添加剂和组合物 |
WO2018114749A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with cystine |
IT201700104536A1 (it) * | 2017-09-19 | 2019-03-19 | Cmed Aesthetics Srl | Prodotti topici con sistema bifasico |
EA202092461A1 (ru) | 2018-05-23 | 2021-02-20 | Юнилевер Н.В. | Наноэмульсии и способ их получения |
CN110090186A (zh) * | 2019-04-08 | 2019-08-06 | 上海添美信息技术有限公司 | 皮肤护理组合物及制备方法 |
CA3160895A1 (en) | 2019-12-10 | 2021-06-17 | Niquette Hunt | Medical devices for generating heat and methods of treatment using the same |
US11576850B1 (en) | 2020-01-06 | 2023-02-14 | Platinum Skin Care, Inc. | Face peel formulation and method of application |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994027569A1 (en) * | 1993-06-01 | 1994-12-08 | Dermatology Home Products, Inc. | Skin treatment method utilizing a composition and a pad |
JPH0748243A (ja) * | 1993-05-27 | 1995-02-21 | Johnson & Johnson Consumer Prod Inc | レチノイド組成物 |
JPH07165567A (ja) * | 1993-10-05 | 1995-06-27 | L'oreal Sa | レチノールを主成分とする化粧または薬理組成物 |
US5505948A (en) * | 1993-06-01 | 1996-04-09 | Dermatology Home Products, Inc. | Home skin peel composition for producing healthy and attractive skin |
JPH11510824A (ja) * | 1996-06-07 | 1999-09-21 | アールオーシー | 皮膚の老化の徴候の処置及び予防のための化粧方法 |
JP2000504689A (ja) * | 1996-02-08 | 2000-04-18 | イー. クリグマン,ダグラス | 表面的化学的皮膚剥脱を実施するための組成物及び方法 |
JP2006169250A (ja) * | 2004-12-17 | 2006-06-29 | L'oreal Sa | 皮膚を手入れする美容方法および関連キット |
ES2255862A1 (es) * | 2004-12-27 | 2006-07-01 | Sesderma, S.L. | Aditivos para peelings cutaneos. |
US20060263398A1 (en) * | 2005-05-23 | 2006-11-23 | Kalil Enterprises, L.L.P. | Method and compound for skin chemical peel |
FR2890309A1 (fr) * | 2005-09-05 | 2007-03-09 | Oreal | Procede cosmetique de soin des peaux grasses et kit associe |
US20090131375A1 (en) * | 1999-06-23 | 2009-05-21 | Dennis Gross | Composition and method for treating skin |
US20100255079A1 (en) * | 2009-04-02 | 2010-10-07 | Sesvalia Usa, Llc | Systems and methods for skin rejuvenation |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3932665A (en) * | 1974-04-05 | 1976-01-13 | Scott Eugene J Van | Process for the treatment of acne vulgaris utilizing retinal |
US4608370A (en) * | 1985-03-04 | 1986-08-26 | Aronsohn Richard B | Skin formulation |
US5133967A (en) * | 1991-06-24 | 1992-07-28 | The Dow Chemical Company | Toning composition and process of using |
US5527530A (en) * | 1994-07-08 | 1996-06-18 | The Procter & Gamble Company | Alcoholic moisturizing after shave lotion |
US5728732A (en) * | 1996-11-27 | 1998-03-17 | Elizabeth Arden Company, Division Of Conopco, Inc. | Skin treatment with salicylic acid esters and retinoids |
DE69828620T2 (de) | 1997-02-25 | 2005-12-01 | The Regents Of The University Of Michigan, Ann Arbor | Verfahren und zusammensetzungen zur vorbeugung und behandlung der chronologischer alterung der menschliches haut |
US5997889A (en) | 1998-02-20 | 1999-12-07 | Omnipotent Skin Products, L.L.C. | Hand and body creme for the treatment of skin ailments |
US6281250B1 (en) * | 1998-04-13 | 2001-08-28 | Southern Research Institute | Retinyl ethers, derivatives and analogues and inhibition of breast carcinogenesis |
US6071541A (en) * | 1998-07-31 | 2000-06-06 | Murad; Howard | Pharmaceutical compositions and methods for managing skin conditions |
US6358517B1 (en) * | 1999-10-22 | 2002-03-19 | Unilever Home & Personal Care Usa, Division Of Conopco | Cosmetic compositions containing resveratrol and retinoids |
WO2001058238A2 (en) | 2000-01-31 | 2001-08-16 | Collaborative Technologies, Inc. | Method and system for producing customized cosmetic and pharmaceutical formulations on demand |
WO2002028361A2 (en) * | 2000-09-29 | 2002-04-11 | Johnson & Johnson Consumer Companies, Inc. | Compositions for cleansing skin and treating acne |
US20050013784A1 (en) * | 2001-02-08 | 2005-01-20 | The Procter & Gamble Company | Mask composition |
DE10117842A1 (de) * | 2001-04-04 | 2002-10-17 | Coty Bv | Kosmetische Vitamin-A-haltige Zubereitung |
KR100477899B1 (ko) * | 2001-04-12 | 2005-03-18 | 구상호 | 레티놀 및 카로틴 화합물의 실용적인 합성방법 |
US20030165546A1 (en) * | 2002-03-04 | 2003-09-04 | The Procter & Gamble Company | Stable personal care compositions containing a retinoid |
US20030215413A1 (en) * | 2002-03-22 | 2003-11-20 | L'oreal | Compositions containing stabilized retinoid |
US20030232091A1 (en) * | 2002-06-17 | 2003-12-18 | Adi Shefer | Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof |
KR20040043703A (ko) | 2002-11-16 | 2004-05-27 | (주)라렌드몽드 | 레티노이드를 함유한 화학 박피제 |
KR100570497B1 (ko) * | 2003-09-18 | 2006-04-13 | 한국콜마 주식회사 | 나노크기의 다중액정막으로 캡슐화된 순수 레티놀을포함하는 주름방지용 화장료 조성물과 이의 제조방법 |
US20080102099A1 (en) | 2004-09-09 | 2008-05-01 | Arturo Jimenez Bayardo | Implants and Microspheres for the Sustained Release of Drugs for Ophthalmic Use and Preparation Methods Thereof |
US20060110416A1 (en) * | 2004-11-23 | 2006-05-25 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Hydroalcoholic cosmetic compositions |
US20060134156A1 (en) | 2004-12-17 | 2006-06-22 | L'oreal | Method for caring for the skin and associated kit |
ITNA20050003A1 (it) * | 2005-01-24 | 2006-07-25 | Rosa Mario De | Peeling gel nano-strutturati |
US20070025949A1 (en) | 2005-07-29 | 2007-02-01 | L'oreal | Compositions and kit for alleviating signs of ageing |
-
2011
- 2011-09-23 US US13/243,567 patent/US10639252B2/en active Active
-
2012
- 2012-09-21 MX MX2014003548A patent/MX370444B/es active IP Right Grant
- 2012-09-21 SG SG10201601101UA patent/SG10201601101UA/en unknown
- 2012-09-21 WO PCT/US2012/056681 patent/WO2013044111A1/en active Application Filing
- 2012-09-21 AU AU2012312090A patent/AU2012312090A1/en not_active Abandoned
- 2012-09-21 KR KR1020147010734A patent/KR102158395B1/ko active IP Right Grant
- 2012-09-21 EP EP12833417.4A patent/EP2758044A4/en not_active Withdrawn
- 2012-09-21 JP JP2014532028A patent/JP6257518B2/ja not_active Expired - Fee Related
- 2012-09-21 SG SG11201400918TA patent/SG11201400918TA/en unknown
- 2012-09-21 CA CA2849893A patent/CA2849893C/en active Active
- 2012-09-21 CN CN202010836689.7A patent/CN111920764A/zh active Pending
- 2012-09-21 CN CN201280057421.7A patent/CN103945838B/zh active Active
-
2014
- 2014-03-24 MX MX2019014952A patent/MX2019014952A/es unknown
-
2015
- 2015-01-28 HK HK15100921.7A patent/HK1200345A1/xx unknown
-
2016
- 2016-04-06 AU AU2016202140A patent/AU2016202140B2/en not_active Ceased
-
2017
- 2017-11-03 AU AU2017254952A patent/AU2017254952A1/en not_active Abandoned
-
2019
- 2019-02-01 AU AU2019200684A patent/AU2019200684A1/en not_active Abandoned
-
2020
- 2020-04-29 US US16/861,449 patent/US20200276094A1/en not_active Abandoned
- 2020-07-17 AU AU2020205329A patent/AU2020205329A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0748243A (ja) * | 1993-05-27 | 1995-02-21 | Johnson & Johnson Consumer Prod Inc | レチノイド組成物 |
WO1994027569A1 (en) * | 1993-06-01 | 1994-12-08 | Dermatology Home Products, Inc. | Skin treatment method utilizing a composition and a pad |
US5505948A (en) * | 1993-06-01 | 1996-04-09 | Dermatology Home Products, Inc. | Home skin peel composition for producing healthy and attractive skin |
US5730991A (en) * | 1993-06-01 | 1998-03-24 | Dermatology Home Products, Inc. | Home skin peel composition for producing healthy and attractive skin |
JPH07165567A (ja) * | 1993-10-05 | 1995-06-27 | L'oreal Sa | レチノールを主成分とする化粧または薬理組成物 |
JP2000504689A (ja) * | 1996-02-08 | 2000-04-18 | イー. クリグマン,ダグラス | 表面的化学的皮膚剥脱を実施するための組成物及び方法 |
JPH11510824A (ja) * | 1996-06-07 | 1999-09-21 | アールオーシー | 皮膚の老化の徴候の処置及び予防のための化粧方法 |
US20090131375A1 (en) * | 1999-06-23 | 2009-05-21 | Dennis Gross | Composition and method for treating skin |
JP2006169250A (ja) * | 2004-12-17 | 2006-06-29 | L'oreal Sa | 皮膚を手入れする美容方法および関連キット |
ES2255862A1 (es) * | 2004-12-27 | 2006-07-01 | Sesderma, S.L. | Aditivos para peelings cutaneos. |
US20060263398A1 (en) * | 2005-05-23 | 2006-11-23 | Kalil Enterprises, L.L.P. | Method and compound for skin chemical peel |
FR2890309A1 (fr) * | 2005-09-05 | 2007-03-09 | Oreal | Procede cosmetique de soin des peaux grasses et kit associe |
US20100255079A1 (en) * | 2009-04-02 | 2010-10-07 | Sesvalia Usa, Llc | Systems and methods for skin rejuvenation |
Non-Patent Citations (2)
Title |
---|
CLINICS IN DERMATOLOGY, vol. 26, JPN6016023755, 2008, pages 200 - 208, ISSN: 0003504107 * |
JOURNAL OF COSMETIC DERMATOLOGY, vol. 4, JPN6016023753, 2005, pages 111 - 116, ISSN: 0003676226 * |
Also Published As
Publication number | Publication date |
---|---|
AU2020205329A1 (en) | 2020-08-06 |
MX370444B (es) | 2019-12-13 |
CA2849893A1 (en) | 2013-03-28 |
WO2013044111A1 (en) | 2013-03-28 |
US20200276094A1 (en) | 2020-09-03 |
EP2758044A1 (en) | 2014-07-30 |
SG11201400918TA (en) | 2014-07-30 |
US20130074860A1 (en) | 2013-03-28 |
MX2014003548A (es) | 2014-06-11 |
JP6257518B2 (ja) | 2018-01-10 |
AU2012312090A1 (en) | 2014-04-17 |
SG10201601101UA (en) | 2016-03-30 |
AU2016202140A1 (en) | 2016-04-28 |
AU2017254952A1 (en) | 2017-11-23 |
AU2016202140B2 (en) | 2017-09-07 |
US10639252B2 (en) | 2020-05-05 |
CN103945838B (zh) | 2020-08-25 |
KR20140069221A (ko) | 2014-06-09 |
KR102158395B1 (ko) | 2020-09-23 |
MX2019014952A (es) | 2020-02-19 |
EP2758044A4 (en) | 2015-06-17 |
CN103945838A (zh) | 2014-07-23 |
HK1200345A1 (en) | 2015-08-07 |
AU2019200684A1 (en) | 2019-02-21 |
CA2849893C (en) | 2017-12-12 |
CN111920764A (zh) | 2020-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6257518B2 (ja) | 皮膚剥脱のための組成物およびその使用 | |
EP1804761B1 (en) | Compositions and methods for treatment of skin discoloration | |
Monheit | Chemical peels | |
US20060222689A1 (en) | Skin care compositions and methods | |
WO2017100873A1 (pt) | Composição cosmética e seu uso | |
US7655255B2 (en) | Topical composition for transdermal administration | |
Tosti et al. | Color atlas of chemical peels | |
US11918666B2 (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
RU2583559C2 (ru) | Средство и способ местного лечения папуло-пустулезной формы розацеа | |
Piquero et al. | Jessner’s peel for the face | |
EP3378474B1 (en) | Composition for the use in the treatment of plantar hyperhidrosis predisposing to cutaneous fungal infection of the foot | |
KR20070006626A (ko) | 피부의 국부조성물 | |
Chan | Use of superficial glycolic acid peels in clinical practice | |
Steiner et al. | Glycolic Acid Peel | |
Ghannam et al. | Chemical Peels in Melasma | |
Singh-Behl et al. | Chemical peels | |
Monheit et al. | Medium depth chemical peels | |
TWI325324B (ja) | ||
Cervantes et al. | Superficial Peeling | |
Khunger et al. | Key Messages | |
Diehl | Chemical peeling in dermatology. Part II. Practical application, complications and their management | |
Langar | Jessner’s and Resorcinol Peels | |
Tedeschi et al. | Chemical peel | |
KR20040024213A (ko) | 홍삼 조사포닌을 함유하는 여드름 개선용 부직포 팩 | |
Zanna | Maximising outcomes with skin peels: products, preparation and procedures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140528 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20150410 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150428 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150909 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160610 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160927 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170529 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170828 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6257518 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |